Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Protocol No
GILEAD-GS-US-577-6153
Principal Investigator
Jonathan Thompson
Phase
III
Summary
The main purpose of this clinical research study is to determine whether treatment with Sacituzumab Govitecan can prolong survival in patients with non-small cell lung cancer (NSCLC) that has progressed after standard cancer therapy.
Description
Phase III trial to determine if treatment with Sacituzumab Govitecan can prolong survival in patients with non-small cell lung cancer who progressed on standard therapy
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
Thoracic Cancers
ClinicalTrials.gov
go to website